Designation of Nusinersen as an orphan drug - Biogen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, is a fundamental piece of legislation that governs the regulation of therapeutic goods in Australia. The Act was introduced to ensure that therapeutic goods available in Australia are of acceptable quality, safety and efficacy, and are appropriately advertised and labelled. One of the ways in which the Act achieves this is through the designation of orphan drugs for rare medical conditions, a policy objective aimed at encouraging the research, development and availability of treatments for conditions that affect a small number of people. In this regard, the Therapeutic Goods Administration has designated Nusinersen as an orphan drug for the treatment of Spinal Muscular Atrophy (SMA), a rare genetic disorder that affects muscle control and movement. The designation of Nusinersen as an orphan drug under the Therapeutic Goods Act 1989 recognises the need for specialised treatments for rare medical conditions, and provides incentives for the research, development and availability of such treatments. The sponsor of Nusinersen, Biogen Australia Pty Ltd, is now eligible for certain benefits and exemptions under the Act, including priority assessment and review of its application for registration, and financial incentives such as grants and tax concessions. This designation helps to ensure that people with SMA and other rare conditions have access to effective and safe treatments, and supports the development of innovative therapies for rare diseases.

Scope and Application

The Therapeutic Goods Act 1989 applies broadly to therapeutic goods, including medicines, medical devices, blood, and tissues, ensuring that they are safe and of high quality. The Act applies to persons and entities involved in the supply, advertising, and sponsorship of therapeutic goods in Australia, encompassing a wide range of industries and conduct related to these goods. Geographically, it operates at the national level, with the Therapeutic Goods Administration overseeing compliance across the Commonwealth of Australia, including states, territories, and national jurisdictions. This Act also extends its application through subordinate instruments, such as regulations and guidelines, to provide detailed provisions and specific exclusions. In this particular designation, Nusinersen has been designated as an orphan drug for the treatment of Spinal Muscular Atrophy (SMA) by Dr. Anthony Gill, acting under the Therapeutic Goods Regulations 1990, which reflects the legislative framework’s flexibility to address specific medical needs through targeted regulatory interventions.

Key Provisions

The Therapeutic Goods Act 1989 (TGA) provides a comprehensive framework for the regulation of therapeutic goods in Australia, including the designation of certain drugs for specific conditions. In the case of Nusinersen, the Therapeutic Goods Regulations 1990 (section 16J) enable the designation of the drug as an orphan drug for the treatment of Spinal Muscular Atrophy (SMA). This designation is made by a Delegate of the Secretary, who has the authority to do so under subregulation 16J(2). The Delegate, Dr Anthony Gill, has exercised this authority by designating Nusinersen as an orphan drug on 21 April 2016, specifically for the treatment of SMA, with the drug presented in the form of a solution for injection (intrathecal injection). The sponsor responsible for this therapeutic good is Biogen Australia Pty Ltd. The designation of Nusinersen as an orphan drug imposes several obligations on the parties involved. The sponsor, Biogen Australia Pty Ltd, must ensure that the drug meets the criteria for orphan drug designation, which typically includes the treatment of rare diseases with limited treatment options. Additionally, the sponsor must comply with all applicable regulations and guidelines set forth by the Therapeutic Goods Administration (TGA). This includes providing necessary documentation, clinical trial data, and ensuring that the drug is manufactured to the required standards. The TGA, in turn, has an obligation to review the application and supporting evidence to ensure that the drug meets the necessary criteria for orphan drug designation. Failure to comply with the obligations imposed by the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can lead to various consequences. The Act outlines both civil and criminal penalties for breaches of its provisions. For instance, if the sponsor fails to provide accurate and complete information, or if the drug does not meet the required standards, they may face civil penalties, including fines. In more severe cases, criminal charges may be pursued, with penalties including imprisonment. The specific maximum penalties are detailed within the Act and depend on the nature and severity of the breach. It is essential for all parties involved to adhere to the regulatory requirements to avoid these potential consequences.